List of Excipients in Branded Drug ARNUITY ELLIPTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	ARNUITY ELLIPTA	fluticasone furoate	0173-0888	LACTOSE MONOHYDRATE	2026-03-01

Arnuity Ellipta Excipient Strategy and Commercial Opportunities

Last updated: August 29, 2026

Arnuity Ellipta is a once-daily dry-powder inhaler containing fluticasone furoate, a corticosteroid for maintenance treatment of asthma. Its commercial formulation uses a short excipient system: lactose monohydrate as the carrier and magnesium stearate as a force-control and moisture-management agent. The main opportunity for excipient suppliers is not replacement of a single ingredient. It is control of particle engineering, carrier-grade lactose, low-dose content uniformity, device compatibility, and regulatory documentation for generic and line-extension products.

Arnuity Ellipta was approved by the FDA in August 2014. The product is marketed in 50 mcg, 100 mcg, and 200 mcg strengths, with delivered doses of 40 mcg, 92 mcg, and 184 mcg, respectively [1]. GlaxoSmithKline, through GSK Consumer Healthcare and later Haleon for certain respiratory assets, has retained the Ellipta platform within the GSK prescription respiratory portfolio.

What excipients are used in Arnuity Ellipta?

Arnuity Ellipta contains micronized fluticasone furoate blended with lactose monohydrate and magnesium stearate.

Component	Role in the product	Commercial significance
Fluticasone furoate	Active pharmaceutical ingredient	Potent, low-dose corticosteroid requiring high blend uniformity
Lactose monohydrate	Carrier and bulking excipient	Controls powder dispersion, metering, blend uniformity, and emitted dose
Magnesium stearate	Force-control and surface-modifying excipient	Reduces adhesion and alters drug-carrier detachment during inhalation
Ellipta inhaler	Multidose foil-blister delivery device	Controls dose storage, puncture, airflow, and patient actuation

The US prescribing information identifies lactose monohydrate and magnesium stearate as inactive ingredients [1]. The formulation is a powder in individual foil blisters rather than a liquid suspension or a conventional capsule-based dry-powder inhaler.

Why lactose is commercially important

Lactose does more than increase formulation mass. In a low-dose inhaled corticosteroid, the carrier influences:

• Drug adhesion to carrier particles
• Detachment during inhalation
• Fine-particle fraction
• Delivered-dose uniformity
• Powder flow through the inhaler
• Sensitivity to humidity and storage conditions
• Manufacturing reproducibility

Carrier lactose is typically selected by particle-size distribution, morphology, surface roughness, crystallinity, moisture content, and trace impurity profile. Ordinary pharmaceutical lactose is not automatically suitable for a high-performance dry-powder inhaler.

Why magnesium stearate is strategically important

Magnesium stearate can coat portions of the carrier and active particles. That coating changes interparticle forces and can improve powder flow. Inhalation formulations require narrow control because excessive surface modification can reduce drug detachment, while insufficient modification can produce poor dose uniformity or high retention in the device.

For Arnuity-type products, magnesium stearate is therefore a formulation-performance excipient rather than a simple lubricant.

How does the Arnuity Ellipta formulation work?

Arnuity Ellipta uses a carrier-based dry-powder architecture. Micronized fluticasone furoate is blended with substantially larger lactose particles. During inhalation, airflow through the device disperses the powder and separates a portion of the active drug from the carrier. The respirable fraction reaches the lower airways.

The commercial performance target is not merely the total labeled dose. It is the aerodynamic particle-size distribution and the amount of active ingredient emitted from the device and converted into fine particles.

Key development parameters include:

Parameter	Relevance
Mass median aerodynamic diameter	Predicts regional lung deposition
Fine-particle fraction	Measures the respirable dose
Emitted dose	Measures delivery from the device
Delivered-dose uniformity	Controls consistency from blister to blister
Blend segregation	Can cause dose variability
Moisture uptake	Can alter cohesion, flow, and device performance
Device retention	Reduces effective patient dose
Stability after foil opening	Affects in-use performance

The Ellipta design separates powder storage from inhaler operation. Each dose is contained in a sealed foil blister that is opened during device use. That configuration reduces exposure to ambient humidity before administration and creates an important interaction between excipient selection and device engineering.

What excipient suppliers can sell into Arnuity-type products?

The most credible commercial opportunities are in qualified inhalation-grade materials and process technologies.

Engineered inhalation-grade lactose

Suppliers can differentiate through:

• Tighter particle-size distributions
• Controlled fines content
• Defined surface-energy profiles
• Low endotoxin and bioburden levels
• Reduced moisture variability
• Better batch-to-batch morphology control
• Regulatory support for inhalation use

The supplier with the strongest position is not necessarily the lowest-cost lactose manufacturer. Generic developers need a material that can be reproduced across commercial batches and supported in an ANDA or other regulatory filing.

Functionalized carrier particles

Surface-treated lactose and engineered carrier systems may improve fine-particle delivery. Opportunities include controlled coating, selective fines addition, and carrier morphology optimization. These technologies can create defensible formulation know-how even where the underlying excipients are off-patent.

The commercial constraint is equivalence. A differentiated carrier must demonstrate comparable or superior aerosol performance without creating a clinically meaningful difference in delivered dose or lung deposition.

Magnesium stearate grades for inhalation

Potential products include magnesium stearate with controlled:

• Specific surface area
• Particle size
• Fatty-acid composition
• Moisture level
• Surface coverage behavior
• Milling and deagglomeration profile

Suppliers can compete through application data showing improved emitted dose, fine-particle fraction, and stability rather than through compendial compliance alone.

Moisture-management materials

The Ellipta blister and foil packaging reduce environmental exposure, but moisture remains a critical development variable. Commercial opportunities exist in:

• High-barrier blister laminates
• Desiccant-compatible secondary packaging
• Low-moisture excipient grades
• Moisture sorption testing
• Inhaler package integrity testing
• Device storage and in-use stability programs

A packaging supplier that can link barrier performance to aerodynamic dose performance has a stronger commercial position than one offering foil alone.

Analytical and development services

Generic inhaler companies require specialized testing for:

• Cascade impactor measurements
• Next-generation impactor testing
• Delivered-dose uniformity
• Aerodynamic particle-size distribution
• Blend uniformity
• Device retention
• Humidity cycling
• Comparative in vitro product performance

These services can be sold as development packages tied to a specific inhaler platform.

What formulation patents protect Arnuity Ellipta?

Protection for Arnuity Ellipta can involve multiple layers:

1. Fluticasone furoate compound and crystalline-form patents
2. Dry-powder composition patents
3. Carrier and surface-modification patents
4. Dose-metering and blister configuration patents
5. Ellipta inhaler device patents
6. Manufacturing and blending processes
7. Method-of-use patents covering once-daily asthma treatment

The commercial formulation may be protected by patents that do not appear to claim lactose or magnesium stearate in isolation. A patent can instead claim a combination of active-particle properties, carrier morphology, excipient ratios, moisture limits, aerosol performance, or device parameters.

This matters for excipient suppliers. A material may be technically suitable but commercially difficult to sell if a generic developer cannot practice the formulation without addressing a device or composition claim.

What is the FDA regulatory status of Arnuity Ellipta?

Arnuity Ellipta is FDA-approved for maintenance treatment of asthma in patients aged five years and older. It is not indicated for acute bronchospasm and is not a rescue inhaler [1].

Milestone	Date or status
FDA approval	August 20, 2014
Active ingredient	Fluticasone furoate
Dosage form	Dry-powder inhalation product
Strengths	50 mcg, 100 mcg, 200 mcg
Administration	Once daily
Pediatric indication	Includes patients aged five years and older
Regulatory pathway for generics	ANDA, subject to FDA requirements for complex inhaled products

The original exclusivity associated with the 2014 approval has expired. Current market access depends primarily on patent status, FDA product-specific guidance, reference-product availability, and the ability to demonstrate pharmaceutical equivalence and bioequivalence for a complex inhaled product.

What is the Orange Book status of Arnuity Ellipta?

The FDA Orange Book is the controlling source for listed patents and exclusivity associated with Arnuity Ellipta [2]. Listed patents may cover the drug substance, formulation, method of use, or delivery system. The practical significance of each listing depends on:

• Whether the patent remains unexpired
• Whether it is listed against the relevant strength and dosage form
• Whether a generic applicant must certify against it
• Whether the patent is vulnerable to invalidity or noninfringement arguments
• Whether the patent covers the reference product or only a specific implementation

An applicant seeking approval of an Arnuity-equivalent product may file Paragraph III or Paragraph IV certifications, depending on the status of listed patents. A Paragraph IV certification can trigger patent litigation under the Hatch-Waxman Act and may create a 30-month stay of approval if the reference-product sponsor files suit within the statutory period [3].

When does Arnuity Ellipta lose exclusivity?

Arnuity's original regulatory exclusivity has expired, but patent-driven market entry depends on the current Orange Book listing and any applicable pediatric or patent-term adjustments.

A practical exclusivity timeline is:

Period	Commercial effect
2014	FDA approval and launch
2014-2017 or later	Original regulatory exclusivity period, depending on the specific statutory basis
After regulatory exclusivity	ANDA filing becomes possible subject to patent certifications
Patent expiration period	Potential generic launch, subject to litigation and FDA review
Post-patent period	Competition shifts toward price, device usability, supply reliability, and payer access

The key distinction is between regulatory exclusivity and patent protection. Regulatory exclusivity can expire while formulation, method-of-use, or device patents remain relevant.

Which companies are challenging Arnuity Ellipta?

Publicly visible generic competition for fluticasone furoate inhalation powder has historically been more limited than competition for older inhaled corticosteroids such as fluticasone propionate. The reasons include:

• Complexity of dry-powder device replication
• Need to match aerodynamic performance
• Device and blister intellectual property
• Low active dose and blend-uniformity requirements
• Limited substitutability between inhaler devices
• Regulatory burden for demonstrating equivalence

Generic applicants may not be required to duplicate the Ellipta device exactly. They must, however, establish equivalence under FDA requirements applicable to inhalation products. A competing inhaler can create commercial friction because pharmacists and patients may not treat different devices as interchangeable in the same way as oral tablets.

No biosimilar pathway applies. Fluticasone furoate is a chemically synthesized small molecule, so potential competitors would use the ANDA pathway rather than a biosimilar application under section 351(k) of the Public Health Service Act.

How strong is the Arnuity Ellipta patent estate?

The estate is commercially stronger when considered as a combined product-and-device system than when considered only as an excipient composition.

Estate component	Relative commercial importance
Fluticasone furoate substance protection	High, but dependent on expiration and claim scope
Lactose and magnesium stearate composition	Moderate unless tied to narrow performance limitations
Device and blister technology	High for exact-device replication
Method-of-use claims	Variable and vulnerable to labeling strategies
Manufacturing processes	Moderate, particularly where process parameters affect performance
Excipient supplier know-how	Commercially important but often protected as confidential know-how rather than patents

Excipient patents alone may not block a generic product if an alternative carrier or lubricant can achieve equivalent aerosol performance. Device claims and formulation-performance claims are more likely to affect launch timing.

What generic launch risks exist for Arnuity Ellipta?

The main generic launch scenarios are:

Early Paragraph IV launch

A generic applicant challenges listed patents and wins litigation, settles on an agreed entry date, or launches at risk. This scenario creates the largest potential price impact but carries substantial patent exposure.

Delayed launch after settlement

The applicant accepts a later entry date in exchange for resolution of litigation. The commercial impact depends on the timing, authorized-generic provisions, and whether multiple applicants receive 180-day exclusivity.

Non-infringing alternative device

A competitor uses a different inhaler architecture and avoids selected device claims. The formulation still must meet FDA equivalence requirements, and substitution may be limited by prescribing and payer behavior.

Formulation redesign

A generic developer changes carrier grade, magnesium stearate level, or particle engineering to avoid composition claims. This creates development risk because changes can affect fine-particle dose, stability, and patient usability.

How does Arnuity Ellipta compare with competing inhaled corticosteroids?

Product	Active ingredient	Dosing pattern	Device/formulation relevance
Arnuity Ellipta	Fluticasone furoate	Once daily	Foil-blister multidose dry powder
Flovent Diskus	Fluticasone propionate	Usually twice daily	Carrier-based dry powder
Asmanex Twisthaler	Mometasone furoate	Once or twice daily, depending on strength	Dry-powder inhaler with distinct device
Pulmicort Flexhaler	Budesonide	Usually twice daily	Breath-actuated dry powder
QVAR RediHaler	Beclomethasone dipropionate	Usually twice daily	Breath-actuated aerosol inhaler

Arnuity's once-daily schedule creates commercial differentiation, but the product remains exposed to therapeutic substitution within the inhaled corticosteroid class. Its formulation and device combination can preserve product-level differentiation after active-ingredient patent barriers weaken.

What licensing deals affect Arnuity Ellipta?

The relevant commercial rights are tied primarily to GSK's fluticasone furoate and Ellipta respiratory platform. GSK developed fluticasone furoate in collaboration with Innoviva, formerly Theravance, under respiratory-development and commercialization arrangements that also covered other respiratory products [4].

For excipient companies, the more realistic licensing opportunities are narrower:

• Exclusive supply of qualified inhalation-grade lactose
• Co-development of carrier morphology
• Licensing of particle-surface treatment
• Contract development and manufacturing
• Access to device-compatible powder-processing technology
• Joint regulatory support for generic or line-extension products

A supplier should expect qualification, change-control, and dual-source requirements. A formulation change involving a critical excipient can require comparability, stability, aerosol-performance, and regulatory documentation.

What revenue exposure does Arnuity create for excipient suppliers?

GSK does not generally report Arnuity excipient procurement as a separate revenue category. Product-specific sales and margin data may also be aggregated within broader respiratory reporting. The opportunity should therefore be assessed through formulation volume, not disclosed excipient revenue.

Revenue drivers include:

• Number of marketed strengths
• Annual inhaler units
• Dose count per inhaler
• Lactose loading per blister
• Magnesium stearate concentration
• Number of approved manufacturing sites
• Generic developer adoption
• Probability of dual sourcing
• Duration of supply contracts

The active ingredient is low dose, so excipient revenue per inhaler is modest. The strategic value is higher when a supplier qualifies across several Ellipta-platform products or wins a generic formulation program.

What geographic opportunities exist?

The strongest opportunities are in markets where fluticasone furoate inhalation products have regulatory recognition and where dry-powder inhaler use is established.

Market	Opportunity
United States	ANDA development, Orange Book patent challenges, inhalation-grade excipient supply
European Union	Generic and hybrid inhaler development, device equivalence, decentralized or centralized regulatory strategies
United Kingdom	Post-Brexit regulatory submissions and NHS procurement
Japan	Local inhaler requirements and device usability considerations
Canada and Australia	Secondary generic markets with established inhaled-corticosteroid demand
Emerging markets	Lower-cost carrier systems, local manufacturing, and supply-chain resilience

Geographic expansion increases the importance of pharmacopeial compliance, local device requirements, stability under elevated humidity, and registration of manufacturing sites.

Key Takeaways

• Arnuity Ellipta uses lactose monohydrate and magnesium stearate in a carrier-based dry-powder formulation.
• The primary excipient opportunity is engineered inhalation-grade lactose with controlled particle size, surface properties, and moisture behavior.
• Magnesium stearate is a performance-critical excipient because it alters interparticle adhesion and drug detachment.
• The strongest commercial barriers are likely to involve the combined formulation, blister, device, and aerosol-performance system.
• Arnuity is a small-molecule product, so biosimilar competition does not apply.
• Generic entry would generally proceed through the ANDA pathway with applicable Paragraph III or Paragraph IV certifications.
• Excipient suppliers can capture value through qualified materials, analytical services, process know-how, and supply agreements rather than through commodity pricing alone.
• Standalone Arnuity revenue and excipient procurement data are not generally disclosed by GSK.

FAQs

Is lactose in Arnuity Ellipta safe for patients with lactose intolerance?

Arnuity Ellipta contains lactose monohydrate, and the lactose may contain trace milk-protein residues. The FDA label identifies this issue for patients with severe milk-protein allergy [1]. Lactose intolerance is clinically distinct from milk-protein allergy.

Can a generic use a different carrier than lactose in an Arnuity-equivalent inhaler?

A generic developer may pursue a different carrier system if it satisfies applicable pharmaceutical-equivalence, performance, stability, and bioequivalence requirements. A carrier substitution can materially change aerosol behavior and may require extensive development.

Does magnesium stearate improve Arnuity Ellipta dose delivery?

Magnesium stearate can reduce cohesive and adhesive forces in a dry powder, but its effect depends on concentration, mixing conditions, particle properties, and humidity. The objective is controlled drug detachment, not simply higher flowability.

Is Arnuity Ellipta interchangeable with Flovent Diskus?

The products contain different fluticasone esters and use different dosing schedules and devices. They should not be treated as automatically interchangeable solely because both are inhaled corticosteroids.

Can an excipient supplier patent a lactose carrier system for an Ellipta-type product?

A supplier may patent particle engineering, surface treatment, composition ranges, manufacturing processes, or aerosol-performance characteristics. Patentability depends on novelty, non-obviousness, enablement, and claim scope.

References

1. U.S. Food and Drug Administration. (2024). Arnuity Ellipta (fluticasone furoate inhalation powder) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards guidance for industry.
4. GlaxoSmithKline plc. (2024). Annual report 2023.